| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tachycardia, Supraventricular | 6 | 2025 | 110 | 2.050 |
Why?
|
| Tachycardia, Ventricular | 10 | 2025 | 255 | 1.950 |
Why?
|
| Arrhythmias, Cardiac | 14 | 2025 | 481 | 1.890 |
Why?
|
| Anti-Arrhythmia Agents | 15 | 2025 | 226 | 1.780 |
Why?
|
| Sotalol | 4 | 2023 | 33 | 1.480 |
Why?
|
| Electrocardiography | 11 | 2025 | 984 | 1.250 |
Why?
|
| Heart Rate | 8 | 2025 | 580 | 1.100 |
Why?
|
| Atrial Flutter | 2 | 2025 | 45 | 1.090 |
Why?
|
| Heart Arrest | 5 | 2022 | 380 | 1.020 |
Why?
|
| Pacemaker, Artificial | 6 | 2025 | 195 | 0.900 |
Why?
|
| Heart Defects, Congenital | 11 | 2025 | 1899 | 0.890 |
Why?
|
| Wolff-Parkinson-White Syndrome | 6 | 2022 | 74 | 0.870 |
Why?
|
| Ventricular Fibrillation | 2 | 2015 | 59 | 0.860 |
Why?
|
| Heart Conduction System | 4 | 2020 | 161 | 0.850 |
Why?
|
| Death, Sudden, Cardiac | 6 | 2022 | 273 | 0.840 |
Why?
|
| Flecainide | 2 | 2021 | 21 | 0.800 |
Why?
|
| Amiodarone | 4 | 2024 | 47 | 0.710 |
Why?
|
| Adenosine | 1 | 2022 | 124 | 0.690 |
Why?
|
| Atrioventricular Block | 2 | 2025 | 46 | 0.670 |
Why?
|
| Cardiopulmonary Resuscitation | 4 | 2021 | 340 | 0.590 |
Why?
|
| Atrial Fibrillation | 6 | 2024 | 734 | 0.550 |
Why?
|
| Heterotaxy Syndrome | 1 | 2017 | 64 | 0.520 |
Why?
|
| Azithromycin | 1 | 2016 | 45 | 0.500 |
Why?
|
| Retrospective Studies | 34 | 2025 | 17667 | 0.500 |
Why?
|
| Echocardiography | 6 | 2024 | 1138 | 0.480 |
Why?
|
| Railroads | 1 | 2015 | 1 | 0.480 |
Why?
|
| Child | 38 | 2025 | 26316 | 0.480 |
Why?
|
| Defibrillators | 1 | 2015 | 22 | 0.470 |
Why?
|
| Urban Health Services | 1 | 2015 | 20 | 0.470 |
Why?
|
| Adolescent | 33 | 2025 | 20994 | 0.460 |
Why?
|
| Electric Countershock | 1 | 2015 | 79 | 0.450 |
Why?
|
| Lidocaine | 2 | 2020 | 41 | 0.450 |
Why?
|
| Exercise Test | 5 | 2020 | 243 | 0.430 |
Why?
|
| Child, Preschool | 25 | 2025 | 15057 | 0.430 |
Why?
|
| Community-Acquired Infections | 1 | 2016 | 254 | 0.430 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 148 | 0.430 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 1 | 2015 | 97 | 0.420 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2025 | 132 | 0.410 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2016 | 284 | 0.400 |
Why?
|
| Pulmonary Artery | 1 | 2016 | 441 | 0.390 |
Why?
|
| Infant | 20 | 2025 | 13324 | 0.380 |
Why?
|
| Coronary Vessels | 1 | 2016 | 529 | 0.370 |
Why?
|
| Follow-Up Studies | 12 | 2025 | 5297 | 0.370 |
Why?
|
| Humans | 59 | 2025 | 131782 | 0.360 |
Why?
|
| Electrocardiography, Ambulatory | 3 | 2024 | 60 | 0.350 |
Why?
|
| Male | 43 | 2025 | 65291 | 0.340 |
Why?
|
| Genetic Testing | 4 | 2025 | 1101 | 0.340 |
Why?
|
| Catheter Ablation | 3 | 2022 | 317 | 0.330 |
Why?
|
| Female | 42 | 2025 | 71223 | 0.320 |
Why?
|
| Cardiomyopathies | 6 | 2022 | 517 | 0.310 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2025 | 204 | 0.300 |
Why?
|
| Time Factors | 8 | 2025 | 6280 | 0.300 |
Why?
|
| Treatment Outcome | 15 | 2025 | 12997 | 0.290 |
Why?
|
| Infant, Newborn | 9 | 2025 | 8597 | 0.260 |
Why?
|
| Propranolol | 3 | 2022 | 111 | 0.260 |
Why?
|
| Survival Rate | 5 | 2020 | 2151 | 0.250 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 2 | 2022 | 32 | 0.250 |
Why?
|
| Heart Failure | 5 | 2023 | 2309 | 0.240 |
Why?
|
| Incidence | 7 | 2020 | 3349 | 0.240 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 2 | 2017 | 73 | 0.230 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2019 | 163 | 0.230 |
Why?
|
| Texas | 7 | 2019 | 3622 | 0.230 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 2 | 2025 | 241 | 0.220 |
Why?
|
| Genetic Variation | 2 | 2025 | 1562 | 0.220 |
Why?
|
| Heart Ventricles | 4 | 2024 | 769 | 0.210 |
Why?
|
| Digoxin | 2 | 2014 | 37 | 0.210 |
Why?
|
| Mass Screening | 3 | 2021 | 825 | 0.210 |
Why?
|
| Cohort Studies | 6 | 2024 | 5122 | 0.210 |
Why?
|
| Hospitals, Pediatric | 4 | 2017 | 793 | 0.200 |
Why?
|
| Marfan Syndrome | 1 | 2024 | 147 | 0.190 |
Why?
|
| Administration, Intravenous | 2 | 2023 | 170 | 0.180 |
Why?
|
| Heart-Assist Devices | 2 | 2025 | 991 | 0.180 |
Why?
|
| Risk Factors | 11 | 2025 | 10965 | 0.180 |
Why?
|
| Defibrillators, Implantable | 2 | 2022 | 214 | 0.180 |
Why?
|
| Long QT Syndrome | 2 | 2019 | 83 | 0.170 |
Why?
|
| Age of Onset | 2 | 2025 | 631 | 0.170 |
Why?
|
| Ataxia | 1 | 2022 | 169 | 0.170 |
Why?
|
| Hospitalization | 4 | 2022 | 1942 | 0.160 |
Why?
|
| Coronary Aneurysm | 1 | 2019 | 31 | 0.150 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2019 | 101 | 0.150 |
Why?
|
| DNA | 1 | 2025 | 1441 | 0.150 |
Why?
|
| Heart Transplantation | 3 | 2023 | 833 | 0.150 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2019 | 45 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2025 | 621 | 0.150 |
Why?
|
| Exercise Tolerance | 1 | 2019 | 89 | 0.150 |
Why?
|
| Risk Assessment | 2 | 2020 | 3696 | 0.150 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2019 | 74 | 0.150 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2020 | 133 | 0.150 |
Why?
|
| Health Policy | 1 | 2021 | 227 | 0.150 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2020 | 173 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 1406 | 0.140 |
Why?
|
| Intellectual Disability | 1 | 2025 | 1082 | 0.140 |
Why?
|
| Hospitals | 1 | 2021 | 445 | 0.140 |
Why?
|
| Disease Progression | 1 | 2024 | 2221 | 0.140 |
Why?
|
| Lung Transplantation | 1 | 2022 | 350 | 0.140 |
Why?
|
| Postoperative Complications | 3 | 2020 | 3134 | 0.130 |
Why?
|
| Death, Sudden | 1 | 2017 | 44 | 0.130 |
Why?
|
| Seizures | 1 | 2022 | 890 | 0.130 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2020 | 359 | 0.130 |
Why?
|
| Fatty Alcohols | 1 | 1996 | 7 | 0.120 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 251 | 0.120 |
Why?
|
| Hospital Mortality | 2 | 2022 | 1076 | 0.120 |
Why?
|
| Penicillins | 1 | 2016 | 154 | 0.120 |
Why?
|
| Cephalosporins | 1 | 2016 | 139 | 0.120 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2016 | 84 | 0.120 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 79 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 432 | 0.120 |
Why?
|
| Young Adult | 7 | 2020 | 10102 | 0.120 |
Why?
|
| Causality | 1 | 2016 | 92 | 0.120 |
Why?
|
| Athletes | 1 | 2016 | 72 | 0.120 |
Why?
|
| Pulmonary Valve | 1 | 2016 | 94 | 0.120 |
Why?
|
| Prognosis | 4 | 2023 | 4953 | 0.120 |
Why?
|
| Sick Sinus Syndrome | 1 | 2015 | 16 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2025 | 3416 | 0.110 |
Why?
|
| NAV1.5 Voltage-Gated Sodium Channel | 1 | 2015 | 41 | 0.110 |
Why?
|
| Muscular Dystrophy, Duchenne | 1 | 2016 | 70 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2017 | 1518 | 0.110 |
Why?
|
| Ventricular Dysfunction | 1 | 2015 | 27 | 0.110 |
Why?
|
| Sex Distribution | 1 | 2016 | 321 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2021 | 791 | 0.110 |
Why?
|
| Circadian Rhythm | 1 | 2017 | 316 | 0.110 |
Why?
|
| Age Distribution | 1 | 2016 | 429 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1626 | 0.110 |
Why?
|
| Radiography, Interventional | 1 | 2015 | 86 | 0.110 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 1996 | 274 | 0.100 |
Why?
|
| Drug Monitoring | 2 | 2013 | 285 | 0.100 |
Why?
|
| Fontan Procedure | 1 | 2016 | 189 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2016 | 457 | 0.100 |
Why?
|
| Ciprofloxacin | 1 | 2013 | 67 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2016 | 1522 | 0.100 |
Why?
|
| Myocardial Ischemia | 1 | 2016 | 310 | 0.100 |
Why?
|
| Stroke Volume | 2 | 2024 | 532 | 0.100 |
Why?
|
| Medical Audit | 1 | 2013 | 96 | 0.100 |
Why?
|
| Ventricular Function, Left | 1 | 2016 | 547 | 0.090 |
Why?
|
| Hypoplastic Left Heart Syndrome | 1 | 2016 | 276 | 0.090 |
Why?
|
| Adult | 11 | 2024 | 31710 | 0.090 |
Why?
|
| Pseudomonas Infections | 1 | 2013 | 117 | 0.090 |
Why?
|
| Mutation | 4 | 2025 | 6194 | 0.090 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2013 | 215 | 0.090 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2016 | 440 | 0.090 |
Why?
|
| Cardiotonic Agents | 1 | 2013 | 136 | 0.090 |
Why?
|
| Exome | 1 | 2017 | 1076 | 0.090 |
Why?
|
| Databases, Factual | 1 | 2016 | 1224 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2016 | 505 | 0.090 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 271 | 0.080 |
Why?
|
| Comorbidity | 1 | 2016 | 1600 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 267 | 0.080 |
Why?
|
| Guideline Adherence | 1 | 2013 | 393 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2017 | 1217 | 0.070 |
Why?
|
| Heart Atria | 2 | 2022 | 336 | 0.070 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 3094 | 0.070 |
Why?
|
| Paraganglioma, Extra-Adrenal | 1 | 2007 | 11 | 0.070 |
Why?
|
| Tachycardia, Ectopic Junctional | 1 | 2007 | 12 | 0.070 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2007 | 31 | 0.070 |
Why?
|
| United States | 6 | 2025 | 11815 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 2299 | 0.070 |
Why?
|
| Phenotype | 3 | 2025 | 4528 | 0.060 |
Why?
|
| Echocardiography, Doppler | 1 | 2006 | 166 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2020 | 838 | 0.060 |
Why?
|
| Mitral Valve Prolapse | 1 | 2024 | 36 | 0.050 |
Why?
|
| Age Factors | 2 | 2025 | 2872 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2023 | 48 | 0.050 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2024 | 173 | 0.050 |
Why?
|
| Equipment Design | 1 | 2025 | 555 | 0.050 |
Why?
|
| Organ Size | 1 | 2024 | 435 | 0.050 |
Why?
|
| Heart Block | 1 | 2022 | 37 | 0.050 |
Why?
|
| Reference Values | 1 | 2024 | 692 | 0.050 |
Why?
|
| Tachycardia | 1 | 2022 | 71 | 0.050 |
Why?
|
| Mitral Valve | 1 | 2024 | 249 | 0.050 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2024 | 183 | 0.050 |
Why?
|
| Verapamil | 1 | 2022 | 48 | 0.050 |
Why?
|
| Prosthesis Design | 1 | 2025 | 611 | 0.050 |
Why?
|
| Isoproterenol | 1 | 2022 | 89 | 0.050 |
Why?
|
| Vesicular Transport Proteins | 1 | 2022 | 141 | 0.040 |
Why?
|
| Magnesium | 1 | 2022 | 121 | 0.040 |
Why?
|
| Bereavement | 1 | 2021 | 20 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 2576 | 0.040 |
Why?
|
| Mitochondrial Proteins | 1 | 2022 | 276 | 0.040 |
Why?
|
| Recurrence | 2 | 2015 | 1483 | 0.040 |
Why?
|
| Acute Disease | 1 | 2023 | 1153 | 0.040 |
Why?
|
| Physicians, Primary Care | 1 | 2021 | 99 | 0.040 |
Why?
|
| LIM Domain Proteins | 1 | 2020 | 67 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2022 | 346 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2021 | 175 | 0.040 |
Why?
|
| Secondary Prevention | 1 | 2021 | 220 | 0.040 |
Why?
|
| Physician's Role | 1 | 2021 | 165 | 0.040 |
Why?
|
| Ankyrins | 1 | 2020 | 96 | 0.040 |
Why?
|
| Cytoskeletal Proteins | 1 | 2020 | 279 | 0.040 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2022 | 464 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 2695 | 0.040 |
Why?
|
| Registries | 1 | 2025 | 1598 | 0.040 |
Why?
|
| Family | 1 | 2021 | 593 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 595 | 0.030 |
Why?
|
| Catecholamines | 1 | 2017 | 50 | 0.030 |
Why?
|
| Calsequestrin | 1 | 2017 | 12 | 0.030 |
Why?
|
| Sleep Deprivation | 1 | 2017 | 44 | 0.030 |
Why?
|
| Telemetry | 1 | 2016 | 25 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 568 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 143 | 0.030 |
Why?
|
| Blood Coagulation Tests | 1 | 1996 | 69 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2022 | 6509 | 0.030 |
Why?
|
| Platelet Aggregation | 1 | 1996 | 104 | 0.030 |
Why?
|
| Pedigree | 1 | 2019 | 1712 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 605 | 0.030 |
Why?
|
| Global Health | 1 | 2020 | 632 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2017 | 750 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 803 | 0.030 |
Why?
|
| Fluoroscopy | 1 | 2015 | 100 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2020 | 1024 | 0.030 |
Why?
|
| Radiation Dosage | 1 | 2015 | 136 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2017 | 500 | 0.030 |
Why?
|
| Databases as Topic | 1 | 2014 | 75 | 0.030 |
Why?
|
| Students | 1 | 2016 | 251 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 510 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 570 | 0.030 |
Why?
|
| Myocarditis | 1 | 2015 | 130 | 0.030 |
Why?
|
| Anorexia | 1 | 2013 | 23 | 0.030 |
Why?
|
| Nausea | 1 | 2013 | 83 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2013 | 97 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2017 | 564 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2017 | 635 | 0.020 |
Why?
|
| Drug Interactions | 1 | 2013 | 241 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2013 | 225 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2993 | 0.020 |
Why?
|
| Patient Safety | 1 | 2017 | 444 | 0.020 |
Why?
|
| Action Potentials | 1 | 2015 | 471 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 1996 | 1638 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1964 | 0.020 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2013 | 175 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2015 | 1235 | 0.020 |
Why?
|
| Middle Aged | 3 | 2017 | 28897 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2015 | 560 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1347 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2020 | 2438 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1838 | 0.020 |
Why?
|
| Reoperation | 1 | 2013 | 844 | 0.020 |
Why?
|
| Pregnancy | 1 | 2022 | 7575 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 2082 | 0.020 |
Why?
|
| Diastole | 1 | 2006 | 179 | 0.020 |
Why?
|
| ROC Curve | 1 | 2006 | 623 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2006 | 1078 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2006 | 3451 | 0.010 |
Why?
|